Alpha-synuclein protein is strongly implicated in the pathogenesis Parkinson's disease. Increased expression of α-synuclein due to genetic multiplication or point mutations leads to early onset disease. While α-synuclein is known to modulate membrane vesicle dynamics, it is not clear if this activity is involved in the pathogenic process or if measurable physiological effects of α-synuclein over-expression or mutation exist in vivo. Macrophages and microglia isolated from BAC α-synuclein transgenic mice, which overexpress α-synuclein under regulation of its own promoter, express α-synuclein and exhibit impaired cytokine release and phagocytosis. These processes were affected in vivo as well, both in peritoneal macrophages and microglia in the CNS. Extending these findings to humans, we found similar results with monocytes and fibroblasts isolated from idiopathic or familial Parkinson's disease patients compared to age-matched controls. In summary, this paper provides 1) a new animal model to measure α-synuclein dysfunction; 2) a cellular system to measure synchronized mobilization of α-synuclein and its functional interactions; 3) observations regarding a potential role for innate immune cell function in the development and progression of Parkinson's disease and other human synucleinopathies; 4) putative peripheral biomarkers to study and track these processes in human subjects. While altered neuronal function is a primary issue in PD, the widespread consequence of abnormal α-synuclein expression in other cell types, including immune cells, could play an important role in the neurodegenerative progression of PD and other synucleinopathies. Moreover, increased α-synuclein and altered phagocytosis may provide a useful biomarker for human PD.
References
[1]
Fink AL (2006) The aggregation and fibrillation of alpha-synuclein. Accounts of Chemical Research 39: 628–634.
[2]
Uversky VN (2008) Alpha-synuclein misfolding and neurodegenerative diseases. Current Protein & Peptide Science 9: 507–540.
[3]
Paleologou KE, Irvine GB, El-Agnaf OM (2005) Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochemical Society Transactions 33: 1106–1110.
[4]
Schiesling C, Kieper N, Seidel K, Kruger R (2008) Review: Familial Parkinson's disease–genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathology & Applied Neurobiology 34: 255–271.
[5]
Lucking CB, Brice A (2000) Alpha-synuclein and Parkinson's disease. Cellular & Molecular Life Sciences 57: 1894–1908.
[6]
Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66–79.
[7]
Kim KS, Park J-Y, Jou I, Park SM (2010) Regulation of Weibel-Palade Body Exocytosis by ？±-Synuclein in Endothelial Cells. Journal of Biological Chemistry 285: 21416–21425.
[8]
Auluck PK, Caraveo G, Lindquist S (2010) -Synuclein: membrane interactions and toxicity in Parkinson's disease. Annual Review of Cell & Developmental Biology 26: 211–233.
[9]
Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, et al. (2010) {alpha}-Synuclein Delays Endoplasmic Reticulum (ER)-to-Golgi Transport in Mammalian Cells by Antagonizing ER/Golgi SNAREs. Mol Biol Cell 21: 1850–1863.
[10]
Ikemura M, Saito Y, Sengoku R, Sakiyama Y, Hatsuta H, et al. (2008) Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67: 945–953.
[11]
Reichmann H (2011) View point: etiology in Parkinson's disease. Dual hit or spreading intoxication. J Neurol Sci 310: 9–11.
[12]
Jellinger KA (2011) Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci 310: 107–111.
[13]
Wakabayashi K, Mori F, Tanji K, Orimo S, Takahashi H (2010) Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol 120: 1–12.
[14]
Halliday GM, Stevens CH (2011) Glia: initiators and progressors of pathology in Parkinson's disease. Mov Disord 26: 6–17.
[15]
Lee SJ (2008) Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Mol Neurosci 34: 17–22.
[16]
Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, Fernandez-Montesinos R, Caro M, et al. (2010) Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants. PLoS ONE 5: e13481.
[17]
Austin SA, Floden AM, Murphy EJ, Combs CK (2006) Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci 26: 10558–10563.
[18]
Erwig LP, Henson PM (2007) Immunological consequences of apoptotic cell phagocytosis. Am J Pathol 171: 2–8.
[19]
Elliott MR, Ravichandran KS (2010) Clearance of apoptotic cells: implications in health and disease. J Cell Biol 189: 1059–1070.
[20]
Braun V, Niedergang F (2006) Linking exocytosis and endocytosis during phagocytosis. Biol Cell 98: 195–201.
[21]
Palokangas H, Mulari M, Vaananen HK (1997) Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts. Journal of Cell Science 110: 1767–1780.
[22]
Hackam DJ, Rotstein OD, Sjolin C, Schreiber AD, Trimble WS, et al. (1998) v-SNARE-dependent secretion is required for phagocytosis. Proceedings of the National Academy of Sciences 95: 11691–11696.
[23]
Huynh KK, Kay JG, Stow JL, Grinstein S (2007) Fusion, Fission, and Secretion During Phagocytosis. Physiology 22: 366–372.
[24]
Murray RZ, Kay JG, Sangermani DG, Stow JL (2005) A Role for the Phagosome in Cytokine Secretion. Science 310: 1492–1495.
[25]
Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, et al. (2010) Alpha-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro. Science 329: 1663–1667.
[26]
Darios F, Ruiperez V, Lopez I, Villanueva J, Gutierrez LM, et al. (2010) [alpha]-Synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis. EMBO Rep 11: 528.
[27]
Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, et al. (2010) Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 19: 1633–1650.
[28]
Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, et al. (2010) Alpha-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro. Science 329: 1663–1667.
[29]
Gu XL, Long CX, Sun L, Xie C, Lin X, et al. (2010) Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain 3: 12.
[30]
Norsworthy PJ, Fossati-Jimack L, Cortes-Hernandez J, Taylor PR, Bygrave AE, et al. (2004) Murine CD93 (C1qRp) Contributes to the Removal of Apoptotic Cells In Vivo but Is Not Required for C1q-Mediated Enhancement of Phagocytosis. The Journal of Immunology 172: 3406–3414.
[31]
Stuart LM, Takahashi K, Shi L, Savill J, Ezekowitz RAB (2005) Mannose-Binding Lectin-Deficient Mice Display Defective Apoptotic Cell Clearance but No Autoimmune Phenotype. The Journal of Immunology 174: 3220–3226.
[32]
Mukundan L, Odegaard JI, Morel CR, Heredia JE, Mwangi JW, et al. (2009) PPAR-[delta] senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med 15: 1266–1272.
[33]
Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, et al. (2005) Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123: 321–334.
[34]
R？szer T, Menéndez-Gutiérrez MP, Lefterova MI, Alameda D, Nú？ez V, et al. (2011) Autoimmune Kidney Disease and Impaired Engulfment of Apoptotic Cells in Mice with Macrophage Peroxisome Proliferator-Activated Receptor γ or Retinoid X Receptor α Deficiency. The Journal of Immunology 186: 621–631.
[35]
Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M (2010) The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6: 280–289.
[36]
Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, et al. (2008) Formation of Toxic Oligomeric α-Synuclein Species in Living Cells. PLoS ONE 3: e1867.
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
[39]
Carr J, de la Fuente-Fernandez R, Schulzer M, Mak E, Calne SM, et al. (2003) Familial and sporadic Parkinson's disease usually display the same clinical features. Parkinsonism Relat Disord 9: 201–204.
[40]
Tan EK, Kwok HH, Tan LC, Zhao WT, Prakash KM, et al. (2010) Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus. Neurology 75: 508–512.
[41]
Brighina L, Prigione A, Begni B, Galbussera A, Andreoni S, et al. (2010) Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease. Neurobiology of Aging 31: 884–885.
[42]
Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37: 510–518.
[43]
Solano RM, Casarejos MJ, Menendez-Cuervo J, Rodriguez-Navarro JA, Garcia de Yebenes J, et al. (2008) Glial dysfunction in parkin null mice: effects of aging. J Neurosci 28: 598–611.
[44]
van Horssen J, Drexhage JA, Flor T, Gerritsen W, van der Valk P, et al. (2010) Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med 49: 1283–1289.
[45]
Miklossy J, Arai T, Guo JP, Klegeris A, Yu S, et al. (2006) LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol 65: 953–963.
[46]
Hasegawa Y, Inagaki T, Sawada M, Suzumura A (2000) Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease. Acta Neurol Scand 101: 159–164.
[47]
Scalzo P, Kummer A, Bretas TL, Cardoso F, Teixeira AL (2010) Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J Neurol 257: 540–545.
[48]
Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl: 277–290.
[49]
Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11: 2395–2407.
[50]
Lotharius J, Brundin P (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3: 932–942.
[51]
Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123: 383–396.
[52]
Rickman C, Davletov B (2005) Arachidonic acid allows SNARE complex formation in the presence of Munc18. Chem Biol 12: 545–553.
[53]
Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, et al. (2010) Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol Biol Cell 21: 1850–1863.
[54]
Burgalossi A, Jung S, Meyer G, Jockusch WJ, Jahn O, et al. (2010) SNARE Protein Recycling by ±SNAP and 2SNAP Supports Synaptic Vesicle Priming. Neuron 68: 473–487.
[55]
Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281: 29739–29752.
[56]
Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, et al. (2001) alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 10: 1847–1851.
[57]
Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164–173.
[58]
Liu J, Cavalli LR, Haddad BR, Papadopoulos V (2003) Molecular cloning, genomic organization, chromosomal mapping and subcellular localization of mouse PAP7: a PBR and PKA-RIalpha associated protein. Gene 308: 1–10.
[59]
Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, et al. (2008) Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 28: 10825–10834.
[60]
Shapiro SS, WIlk MB (1965) An analysis of varianace test for normality. Biometrikal 52: 591–611.
[61]
Levene H, Ingram O, Hotelling H, et al. (1960) Contributions to Probability and Statistics: Essays in Honor of Harold Htelling.: Standford Univeristy Press.
